Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents

Current Cancer Drug Targets

Volumn 1, Issue 2, 2001, Pages 129-140

  Ghosh, Sutapa ^a   Liu, Xing Ping ^a   Zheng, Yaguo ^a   Uckun, Fatih M ^a  

^a Parker Hughes Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND;

AUDIOVISUAL EQUIPMENT; CELL DIVISION; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; HUMAN; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, STRUCTURAL; MOLECULAR STRUCTURE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0035428019     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334188     Document Type: Article

References (54)

1. Aaronson, S. A. Growth Factors and Cancer. Science 1991,254, 1146-1152.
2. Hanks, S. K.; Hunter, T. Protein Kinases 6. The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification. FASEB J. 1995, 9, 576-96.
3. Traxler, P.; Furet, P. Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacol Ther. 1999, 82, 195-206.
4. Raymond, E.; Faivre, S.; Armand, J. P. Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy. Drugs 2000, 60, Suppl 1, 15-2.
5. Todderud, G.; Carpenter, G. Epidermal Growth Factor: The Receptor and its Function. Biofactors 1989,2, 1115.
6. Ross, J. S.; Fletcher, J. A. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 1998, 3, 237-252.
7. Toi, M.; Osaki, A.; Yamada, H.; Toge, T. Epidermal Growth'Factor Receptor Expression as a Prognostic Indicator in Breast Cancer. Eur. J. Cancer 1991, 27, 97780.
8. Chrysogelos, S.; Dickson, R. EOF Receptor Expression, Regulation, and Function in Breast Cancer. Breast CancerRes. Treat. 1994, 29, 29-40.
9. George-Nascimento, C.; Gyenes, A.; Halloran, S. M.; Merryweather, J.; Valenzuela, P.; Steimer, K. S.; Masiarz, F. R.; Randolph, A. Characterization of Recombinant Human Epidermal Growth Factor Produced in Yeast. Biochemistry 1988, 27, 797-802.
10. Khazaie, K.; Schirrmacher, V.; Lichtner, R. EGF Receptor in Neoplasia and Metastasis. Cancer Metasis Rev. 1993, 12, 255-74.
11. Fry, D. W.; Bridges, A. J. Inhibitors of Protein Tyrosine Kinases. Curr. Opin. Biotechnol. 1995, 6, 662-667.
12. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase by 4-anilinoquinazolines. Breast Cancer Research and Treatment 1996, 38, 67-73.
13. Lawrence, D. S.; Niu, J. Protein Kinase Inhibitors: The Tyrosine-Specific Protein Kinases. Pharmacol. Ther. 1998,77, 81-114.
14. Earp, H. S.; Dawson, T. L.; Li, X.; Yu, H. Heterodimerization and Functional Interaction between EGF Receptor Family Members: A New Signaling Paradigm with Implications for Breast Cancer Research. Breast Cancer Res. Treat. 1995,35, 115-132.
15. Wright, J. D.; Reuter, C. W.; Weber, M. J. An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-Defective Epidermal Growth Factor Receptors. J. Biol. Chem. 1995, 270, 12085-93.
16. Arteaga, C. L.; Hurd, S. D.; Dugger, T. C.; Winnier, A. R.; Robertson, J. B. Epidermal Growth Factor Receptors in Human Breast Carcinoma Cells: A Potential Selective Target for Transforming Growth Factor AlphaPseudomonas Exotoxin 40 Fusion Protein. Cancer Res. 1994, 54, 4703-9.
17. Fan, Z.; Mendelsohn, J. Therapeutic Application of AntiGrowth Factor Receptor Antibodies. Curr. Opin. Oncol. 1998,10, 67-73.
18. Ciardiello, F. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents. Drugs 2000, 60 Suppl. 1,25-32.
19. Uckun, F. M.; Jun, X.; Narla, R. K.; Zeren, T.; Venkatachalam, T.; Waddick, K.; Rostostev, A.; Myers, D. E. Cytotoxic Activity of EGF-Genistein Against Human Breast Cancer Cells. Clin. Cancer Res. 1998, 4, 901-912.
20. Uckun, F. M.; Narla, R. K.; Zeren, T.; Yanishevski, Y.; Myers, D. E.; Waurzyniak, B.; Ek, O.; Schneider, E.; Messinger, Y.; Chelstrom, L. M.; Günther, R.; Evans, W. In Vivo Toxicity, Pharmacokinetics, and Anticancer Activity of Genistein Linked to Recombinant Human Epidermal Growth Factor. Clin. Cancer Res. 1998, 4, 1125-1134.
21. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.; Itoh, N.; Shibuya, M.; Fukami, Y. Genistein, a Specific Inhibitor of Tyrosine-Specific Protein Kinases. J. Biol. Chem. 1987,262, 5592-5595.
22. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4(Phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
23. Moyer, J. D,; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of Apoptosis and Cell Cycle Arrest by CP358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase. Cancer Res. 1997, 57, 48384848.
24. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science 1994, 265, 10931095.
25. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues -of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent inhibitor of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 267-276.
26. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor. Proc. Natl. Acad. Sei. USA 1998, 95, 12022-12027.
27. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI571 [inhibition of Abelson Tyrosine Kinase. Science 2000, 289, 1938-1942.
28. Zheng, J.; Knighton, D. R.; Ten Eyck, L. F.; Karlsson, R.; Xuong, N.; Taylor, S. S.; Sowadski, J. M. Crystal Structure of the Catalytic Subunit of cAMP-Dependent Protein Kinase Complexed with MgATP and Peptide Inhibitor. Biochemistry 1993,32, 2154-61.
29. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(PhenyIamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1996, 39, 2285-2292.
30. Traxler, P.; Green, J.; Mett, H.; Sequin, U.; Furet, P. Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl4(1H)-quinolones. J. Med. Chem. 1999,42, 1018-1026.
31. [31 ] Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D.; Denny, W. A. Tyrosine Kinase Knhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding. J. Med. Chem. 1991,40, 1519-1529.
32. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Hollis Showalter, H. D. Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
33. Ghosh, S.; Zheng, Y.; Jun, X.; Narla, R.; Mahajan, S.; Navara, C.; Mao, C.; Sudbeck, E. A.; Uckun, F. M. aCyano-j8-hydroxy-/3-methyl-W-[4-(trifluoromethoxy)phenyl]propenamide: An Inhibitor of the EGF Receptor Tyrosine Kinase with Potent Cytotoxic Activity against Breast Cancer Cells. Clin. Can. Res. 1998, 4, 2657-2668.
34. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal Structure of the Src Family Tyrosine Kinase Hck. Nature 1997, 385, 602609.
35. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science 1997, 276, 955-960.
36. Hubbard, S. R. Crystal Structure of the Activated Insulin Receptor Tyrosine Kinase in Complex with Peptide Substrate and ATP Analog. EMBO J. 1997, 16, 55725581.
37. Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadski, J. M. 2.2Ä Refined Crystal Structure of the Catalytic Subunit of cAMP-Dependent Protein Kinase Complexed with Mn, ATP and a Peptide Inhibitor. Acta Cryst. 1993, D49, 362-365.
38. Parnham, M. J. Leflunomide : A Potential New Disease Modifying Anti-rheumatic Drug. Expert Opin. Invest. Drugs 1995, 4, 777-779.
39. Xu, X.; Williams, J. W.; Gong, H.; Finnegan, A.; Chong, A. S. Two Activities of the Immunosuppressive Metabolite of Leflunomide, A77 1726. Inhibition of Pyrimidine Nucleotide Synthesis and Protein Tyrosine Phosphorylation. Biochem. Pharmacol. 1996, 52, 527534.
40. Mattar, T.; Kochhar, K.; Bartlett, R.; Bremer, E. G.; Finnegan, A. Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Activity by Leflunomide. FEBS Lett. 1993, 334; 161-164.
41. Ghosh, S.; Narla, R. K.; Zheng, Y.; Liu, X.-P.; Jun, X.; Mao, C.; Sudbeck, E. A.; Uckun, F. M. Structure-Based Design of Potent Inhibitors of EGF-Receptor Tyrosine Kinase as Anti-cancer Agents. Anticancer Drug Des. 1999, 403-410.
42. Ghosh, S.; Uckun, F. M. alpha-Cyano-N-(2,5dibromophenyl)-beta-hydroxybut-2-enamide. Act a Cryst. C 1999, 55, 1364-1365.
43. Ghosh, S.; Zheng, Y.; Uckun, F. M. Five Analogs of the Active Metabolite of Leflunomide. Acta Cryst. C 1999, 55, 2117-2122.
44. Ghosh, S.; Jennissen, J. D.; Zheng, Y.; Uckun, F. M. Three Leflunomide Metabolite Analogs. Acta Cryst. C 2000,56, 1254-1257.
45. Sudbeck, E. A.; Jennissen, J. D.; Liu, X.-P.; Uckun, F. M. An Inhibitor of Janus Kinase 3: 4-(4HydroxyphenyIamino)-6,7-dimethoxyquinazolin-l-ium Chloride Methanol Solvate. Acta Cryst. C 2000, 56 1282-1283.
46. Ghosh, S.; Jennissen, J. D.; Liu, X.-P.; Uckun, F. M. 4[(3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate and 4-[(3Hydroxyphenyl)amino]-6,7-dimethoxy-l-quinazolinium Chloride. Acta Cryst. C 2001, 57, 76-78.
47. Sudbeck, E. A.; Liu, X.-P.; Narla, R. K.; Mahajan, S.; Ghosh, S.; Mao, C.; Uckun, F. M. Structure-Based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-Inducing Anti-leukemic Agents. Clin. Cancer Res. 1999, 5, 1569-1582.
48. Mahajan, S.; Ghosh,.S.; Sudbeck, E. A.; Zheng, Y.; Downs, S.; Hupke, M.; Uckun, F. M. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK): LFM-A13 [a-Cyano-hydroxy-methyl-N-(2,5-dibromophenyl)propenamide]. J. Biol. Chem. 1999, 274, 9587-9599.
49. Narla, R. K.; Liu, X.-P.; Myers, D. E.; Uckun, F. M. 4-(3'Bromo-4' hydroxyIphenyl)-amino-6,7dimethoxyquinazoline: A Novel Quinazoline Derivative with Potent Cytotoxic Activity Against Human Glioblastoma Cells. Clin. Can. Res. 1998,4, 1405-1414.
50. Bacon, D. J.; Anderson, W. F. A Fast Algorithm for Rendering Space-Filling Molecule Pictures. J. Molec. Graphics 1988, 6, 219-220.
51. Kraulis, P. MOLSCR1PT: A Program to Produce both Detailed and Schematic Plots of Proteins. J. Appl Cryst. 1991,24, 946-950.
52. Merritt, E. A.; Murphy, M. E. P. Raster3D Version 2.0 A Program for Photorealistic Molecular Graphics. Acta Cryst. D 1994, 50, 869-873.
53. Bohm, H. J. LUDI: Rule-Based Automatic Design of New Substituents for Enzyme Inhibitor Leads. J. Comput. Aided Mol Des. 1992, 6, 593-606.
54. Bohm, H. J. The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure. J. Comput. Aided Mol. Des. 1994, 8, 243-256.